Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | = 0.017 microM | Growth inhibition of human HCT15 cells after 3 days by crystal violet staining | ChEMBL. | 19954252 |
GI50 (functional) | = 0.018 microM | Growth inhibition of human NCI-H460 cells after 3 days by crystal violet staining | ChEMBL. | 19954252 |
GI50 (ADMET) | = 0.017 uM | Cytotoxicity against MDR HCT15 cells | ChEMBL. | 16950621 |
GI50 (ADMET) | = 0.017 uM | Cytotoxicity against MDR HCT15 cells | ChEMBL. | 16950621 |
GI50 (ADMET) | = 0.018 uM | Cytotoxicity against NCI-H460 cells | ChEMBL. | 16950621 |
GI50 (ADMET) | = 0.018 uM | Cytotoxicity against NCI-H460 cells | ChEMBL. | 16950621 |
IC50 (functional) | = 0.54 microM | Cytotoxicity against HUVEC after 72 hrs by crystal violet staining | ChEMBL. | 19954252 |
IC50 (functional) | = 28.3 microM | Cytotoxicity against HUVEC after 1 hr by crystal violet staining | ChEMBL. | 19954252 |
IC50 (functional) | = 41.5 microM | Vascular disrupting activity in HUVEC assessed as change in cell morphology with detachment form substrate after 1 hr by crystal violet staining-based inverted light microscopy | ChEMBL. | 19954252 |
Log TGI (ADMET) | = 4.4 | Cytotoxicity against NCI60 cell line | ChEMBL. | 16950621 |
Log TGI (functional) | = 7.53 | Tumor growth inhibition against HCC2998 cells | ChEMBL. | 16950621 |
pGI50 (ADMET) | = 7.14 | Cytotoxicity against NCI60 cell line | ChEMBL. | 16950621 |
TGI (functional) | = -7.53 | Tumor growth inhibition against HCC2998 cells | ChEMBL. | 16950621 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 19954252 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.